SG11202107919YA - The monohydrate of rogaratinib hydrochloride and solid states thereof - Google Patents

The monohydrate of rogaratinib hydrochloride and solid states thereof

Info

Publication number
SG11202107919YA
SG11202107919YA SG11202107919YA SG11202107919YA SG11202107919YA SG 11202107919Y A SG11202107919Y A SG 11202107919YA SG 11202107919Y A SG11202107919Y A SG 11202107919YA SG 11202107919Y A SG11202107919Y A SG 11202107919YA SG 11202107919Y A SG11202107919Y A SG 11202107919YA
Authority
SG
Singapore
Prior art keywords
rogaratinib
monohydrate
hydrochloride
solid states
states
Prior art date
Application number
SG11202107919YA
Inventor
Jörg Gries
Johannes Platzek
Claus-Christian Häselhoff
Kai Lovis
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of SG11202107919YA publication Critical patent/SG11202107919YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
SG11202107919YA 2019-01-31 2020-01-27 The monohydrate of rogaratinib hydrochloride and solid states thereof SG11202107919YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19154781 2019-01-31
PCT/EP2020/051884 WO2020156982A1 (en) 2019-01-31 2020-01-27 The monohydrate of rogaratinib hydrochloride and solid states thereof

Publications (1)

Publication Number Publication Date
SG11202107919YA true SG11202107919YA (en) 2021-08-30

Family

ID=65276007

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107919YA SG11202107919YA (en) 2019-01-31 2020-01-27 The monohydrate of rogaratinib hydrochloride and solid states thereof

Country Status (21)

Country Link
US (1) US20220098201A1 (en)
EP (1) EP3917929A1 (en)
JP (1) JP2022519081A (en)
KR (1) KR20210119994A (en)
CN (1) CN113382997A (en)
AU (1) AU2020214188A1 (en)
BR (1) BR112021012876A2 (en)
CA (1) CA3128073A1 (en)
CL (1) CL2021001977A1 (en)
CO (1) CO2021009660A2 (en)
DO (1) DOP2021000162A (en)
EA (1) EA202192133A1 (en)
EC (1) ECSP21056314A (en)
GE (1) GEP20237531B (en)
IL (1) IL284927A (en)
JO (1) JOP20210204A1 (en)
MA (1) MA54856A (en)
MX (1) MX2021009173A (en)
SG (1) SG11202107919YA (en)
TW (1) TW202035413A (en)
WO (1) WO2020156982A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406162B2 (en) * 2015-03-09 2019-09-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations
CN113720956B (en) * 2021-09-08 2022-03-29 广州国标检验检测有限公司 Method for detecting sulfate in medicine by gas chromatography-mass spectrometry

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618622A2 (en) * 2005-11-17 2011-09-06 Osi Pharm Inc compound, composition, and use of a compound
PE20070855A1 (en) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
CN101389630A (en) * 2005-12-29 2009-03-18 艾博特公司 Protein kinase inhibitors
UY34484A (en) * 2011-12-15 2013-07-31 Bayer Ip Gmbh BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES

Also Published As

Publication number Publication date
CL2021001977A1 (en) 2022-02-25
JP2022519081A (en) 2022-03-18
KR20210119994A (en) 2021-10-06
WO2020156982A1 (en) 2020-08-06
DOP2021000162A (en) 2021-09-15
JOP20210204A1 (en) 2023-01-30
EP3917929A1 (en) 2021-12-08
ECSP21056314A (en) 2021-08-31
CO2021009660A2 (en) 2021-08-09
CN113382997A (en) 2021-09-10
AU2020214188A1 (en) 2021-07-15
TW202035413A (en) 2020-10-01
GEP20237531B (en) 2023-08-25
US20220098201A1 (en) 2022-03-31
CA3128073A1 (en) 2020-08-06
MA54856A (en) 2022-05-04
EA202192133A1 (en) 2022-02-09
MX2021009173A (en) 2021-09-10
IL284927A (en) 2021-09-30
BR112021012876A2 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
IL282487A (en) Tyk2 inhibitors and uses thereof
IL288062A (en) Solid state forms of tafamidis and salts thereof
IL285178A (en) Compounds and uses thereof
ZA202106304B (en) Heterocyclic compound and use thereof
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
IL286248A (en) Tyk2 inhibitors and uses thereof
IL284799A (en) Tyk2 inhibitors and uses thereof
IL282090A (en) Tyk2 inhibitors and uses thereof
IL283409A (en) Tyk2 inhibitors and uses thereof
IL285177A (en) Compounds and uses thereof
IL277694A (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
IL284514A (en) Halo-allylamine compounds and use thereof
IL284927A (en) The monohydrate of rogaratinib hydrochloride and solid states thereof
IL287026A (en) Heterocyclic compounds and uses thereof
SG11202110225SA (en) Compounds and uses thereof
IL291499A (en) Aza-quinoline compounds and uses thereof
IL284764A (en) Compounds and uses thereof
IL281357B (en) Cd73 inhibitors and pharmaceutical uses thereof
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
IL285118A (en) Compounds and uses thereof
IL285461A (en) Processes and compounds
EP4074709A4 (en) Monocyclic beta-lactam compound and use thereof
IL289531A (en) Cd38-binding agents and uses thereof
IL288828A (en) Cd38-binding agents and uses thereof
IL284843A (en) Carbamate derivatives and uses thereof